Expression of GPX4 by oncolytic vaccinia virus can significantly enhance CD8⁺T cell function and its impact against pancreatic ductal adenocarcinoma

References

• Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17–14. doi:10.3322/caac.21763.
   PubMed Web of Science ®Google Scholar
• Wood LD, Canto MI, Jaffee EM, Simeone DM. Pancreatic cancer: pathogenesis, screening, diagnosis, and treatment. Gastroenterology. 2022;163(2):386–402 e381. doi:10.1053/j.gastro.2022.03.056.
   PubMed Web of Science ®Google Scholar
• Farren MR, Sayegh L, Ware MB, Chen H-R, Gong J, Liang Y, Krasinskas A, Maithel SK, Zaidi M, Sarmiento JM, et al. Immunologic alterations in the pancreatic cancer microenvironment of patients treated with neoadjuvant chemotherapy and radiotherapy. JCI Insight. 2020;5(1):Insight 5: 2020. doi: 10.1172/jci.insight.130362.
   PubMed Web of Science ®Google Scholar
• Halbrook CJ, Lyssiotis CA, Pasca di Magliano M, Maitra A. Pasca di Magliano M and Maitra A: pancreatic cancer: advances and challenges. Cell. 2023;186(8):1729–1754. doi:10.1016/j.cell.2023.02.014.
   PubMed Web of Science ®Google Scholar
• Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, Coussens LM, Gabrilovich DI, Ostrand-Rosenberg S, Hedrick CC, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24(5):541–550. doi:10.1038/s41591-018-0014-x.
   PubMed Web of Science ®Google Scholar
• Fan JQ, Wang MF, Chen HL, Shang D, Das JK, Song J. Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma. Mol Cancer. 2020;19(1):32. doi:10.1186/s12943-020-01151-3.
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Tykodi SS, Chow LQ, Hwu W-J, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, et al. Safety and activity of anti–PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455–2465. doi:10.1056/NEJMoa1200694.
   PubMed Web of Science ®Google Scholar
• Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350–1355. doi:10.1126/science.aar4060.
   PubMed Web of Science ®Google Scholar
• Bear AS, Vonderheide RH, O’Hara MH. Challenges and opportunities for pancreatic cancer immunotherapy. Cancer Cell. 2020;38(6):788–802. doi:10.1016/j.ccell.2020.08.004.
   PubMed Web of Science ®Google Scholar
• Lawler SE, Speranza MC, Cho CF, Chiocca EA. Oncolytic viruses in cancer treatment: a review. JAMA Oncol. 2017;3(6):841–849. doi:10.1001/jamaoncol.2016.2064.
   PubMed Web of Science ®Google Scholar
• Tian Y, Xie D, Yang L. Engineering strategies to enhance oncolytic viruses in cancer immunotherapy. Signal Transduct Target Ther. 2022;7(1):117. doi:10.1038/s41392-022-00951-x.
   PubMed Web of Science ®Google Scholar
• Guo ZS, Lu B, Guo Z, Giehl E, Feist M, Dai E, Liu W, Storkus WJ, He Y, Liu Z, et al. Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics. J Immunother Cancer. 2019;7(1):6. doi:10.1186/s40425-018-0495-7.
   PubMedGoogle Scholar
• Kaufman HL, Deraffele G, Mitcham J. Moroziewicz, D., Cohen, S.M, Hurst-Wicker, K.S., Cheung, K., Lee, D.S., Divito, J., Voulo, M., Donovan, J, et al. Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanoma. J Clin Invest. 2005;115(7):1903–1912. doi:10.1172/JCI24624.
   PubMed Web of Science ®Google Scholar
• Eriksson E, Milenova I, Wenthe J, Ståhle M, Leja-Jarblad J, Ullenhag G, Dimberg A, Moreno R, Alemany R, Loskog A, et al. Shaping the tumor stroma and sparking immune activation by CD40 and 4-1BB signaling induced by an armed oncolytic virus. Clin Cancer Res. 2017;23(19):5846–5857. doi:10.1158/1078-0432.CCR-17-0285.
   PubMed Web of Science ®Google Scholar
• Robinson M, Li B, Ge Y, Ko D, Yendluri S, Harding T, VanRoey M, Spindler KR, Jooss K. Novel immunocompetent murine tumor model for evaluation of conditionally replication-competent (oncolytic) murine adenoviral vectors. J Virol. 2009;83(8):3450–3462. doi:10.1128/JVI.02561-08.
   PubMed Web of Science ®Google Scholar
• Li J, O’Malley M, Urban J, Sampath P, Guo ZS, Kalinski P, Thorne SH, Bartlett DL. Chemokine expression from oncolytic vaccinia virus enhances vaccine therapies of cancer. Mol Ther. 2011;19(4):650–657. doi:10.1038/mt.2010.312.
   PubMed Web of Science ®Google Scholar
• Li F, Sheng Y, Hou W, Sampath P, Byrd D, Thorne S, Zhang Y. CCL5-armed oncolytic virus augments CCR5-engineered NK cell infiltration and antitumor efficiency. J Immunother Cancer. 2020;8(1):e000131. doi:10.1136/jitc-2019-000131.
   PubMed Web of Science ®Google Scholar
• Shinsuke Nakao YA, Tasaki M, Yamashita M, Murakami R, Tatsuya Kawase NA, Nakatake M, Kurosaki H, Mori M, Takeuchi M, Mori M. Takafumi Nakamura: intratumoral expression of IL-7 and IL-12 using an oncolytic virus increases systemic sensitivity to immune checkpoint blockade. Sci Transl Med. 2020;12(526):eaax7992. doi:10.1126/scitranslmed.aax7992.
   PubMed Web of Science ®Google Scholar
• Pearl TM, Markert JM, Cassady KA, Ghonime MG. Oncolytic virus-based cytokine expression to improve immune activity in brain and solid tumors. Mol Ther Oncolytics. 2019;13:14–21. doi:10.1016/j.omto.2019.03.001.
   PubMed Web of Science ®Google Scholar
• Barber S, Barber GN. Oncolytic viruses as antigen agnostic tumor vaccines. Cancer Cell. 2018;33(4):599–605. doi:10.1016/j.ccell.2018.03.011.
   PubMed Web of Science ®Google Scholar
• Tian C, Liu J, Zhou H, Li J, Sun C, Zhu W, Yin Y, Li X. Enhanced anti-tumor response elicited by a novel oncolytic HSV-1 engineered with an anti-PD-1 antibody. Cancer Lett. 2021;518:49–58. doi:10.1016/j.canlet.2021.06.005.
   PubMed Web of Science ®Google Scholar
• Lei GL, Wang LP, Dong SH, Sun F, Cheng J-X, Yang X-L, Zhang S-G, Wang X-L, Wang X-X, Yang P-H, et al. A recombinant influenza virus with a CTLA4-specific scFv inhibits tumor growth in a mouse model. Cell Biol Int. 2021;45(6):1202–1210. doi:10.1002/cbin.11559.
   PubMed Web of Science ®Google Scholar
• Qiao J, Kottke T, Willmon C, Galivo F, Wongthida P, Diaz RM, Thompson J, Ryno P, Barber GN, Chester J, et al. Purging metastases in lymphoid organs using a combination of antigen-nonspecific adoptive T cell therapy, oncolytic virotherapy and immunotherapy. Nat Med. 2008;14(1):37–44. doi:10.1038/nm1681.
   PubMed Web of Science ®Google Scholar
• Willmon C, Harrington K, Kottke T, Prestwich R, Melcher A, Vile R. Cell carriers for oncolytic viruses: fed ex for cancer therapy. Mol Ther. 2009;17(10):1667–1676. doi:10.1038/mt.2009.194.
   PubMed Web of Science ®Google Scholar
• Zheng N, Fang J, Xue G, Wang Z, Li X, Zhou M, Jin G, Rahman MM, McFadden G, Lu Y, et al. Induction of tumor cell autosis by myxoma virus-infected CAR-T and TCR-T cells to overcome primary and acquired resistance. Cancer Cell. 2022;40(9):973–985 e977. doi:10.1016/j.ccell.2022.08.001.
   PubMed Web of Science ®Google Scholar
• Iankov ID, Blechacz B, Liu C, Schmeckpeper JD, Tarara JE, Federspiel MJ, Caplice N, Russell SJ. Infected cell carriers: a new strategy for systemic delivery of oncolytic measles viruses in cancer virotherapy. Mol Ther. 2007;15(1):114–122. doi:10.1038/sj.mt.6300020.
   PubMed Web of Science ®Google Scholar
• Yu F, Wang X, Guo ZS, Bartlett DL, Gottschalk SM, Song XT. T-cell engager-armed oncolytic vaccinia virus significantly enhances antitumor therapy. Mol Ther. 2014;22(1):102–111. doi:10.1038/mt.2013.240.
   PubMed Web of Science ®Google Scholar
• Yang WS, SriRamaratnam R, Welsch ME, Shimada K, Skouta R, Viswanathan V, Cheah J, Clemons P, Shamji A, Clish C, et al. Regulation of ferroptotic cancer cell death by GPX4. Cell. 2014;156(1–2):317–331. doi:10.1016/j.cell.2013.12.010.
   PubMed Web of Science ®Google Scholar
• Zou Y, Palte MJ, Deik AA, Li H, Eaton JK, Wang W, Tseng Y-Y, Deasy R, Kost-Alimova M, Dančík V, et al. A GPX4-dependent cancer cell state underlies the clear-cell morphology and confers sensitivity to ferroptosis. Nat Commun. 2019;10(1):2019. doi:10.1038/s41467-019-09277-9.
   PubMedGoogle Scholar
• Eaton JF, Ruberto RA, Moosmayer D, Hilpmann A, Ryan MJ, Zimmermann K, Cai LL, Niehues M, Badock V, Kramm A, et al. Selective covalent targeting of GPX4 using masked nitrile-oxide electrophiles. Nat Chem Biol. 2020;5(5):497–506. doi:10.1038/s41589-020-0501-5.
   Google Scholar
• Drijvers JM, Gillis JE, Muijlwijk T, Nguyen TH, Gaudiano EF, Harris IS, LaFleur MW, Ringel AE, Yao C-H, Kurmi K, et al. Pharmacologic screening identifies metabolic vulnerabilities of CD8(+) T cells. Cancer Immunol Res. 2021;9(2):184–199. doi:10.1158/2326-6066.CIR-20-0384.
   PubMed Web of Science ®Google Scholar
• Yang K, Wang X, Song C, He Z, Wang R, Xu Y, Jiang G, Wan Y, Mei J, Mao W, et al. The role of lipid metabolic reprogramming in tumor microenvironment. Theranostics. 2023;13(6):1774–1808. doi:10.7150/thno.82920.
   PubMed Web of Science ®Google Scholar
• Gubser PM, Bantug GR, Razik L, Fischer M, Dimeloe S, Hoenger G, Durovic B, Jauch A, Hess C. Rapid effector function of memory CD8+ T cells requires an immediate-early glycolytic switch. Nat Immunol. 2013;14(10):1064–1072. doi:10.1038/ni.2687.
   PubMed Web of Science ®Google Scholar
• Yu W, Lei Q, Yang L, Qin G, Liu S, Wang D, Ping Y, Zhang Y. Contradictory roles of lipid metabolism in immune response within the tumor microenvironment. J Hematol Oncol. 2021;14(1):187. doi:10.1186/s13045-021-01200-4.
   PubMed Web of Science ®Google Scholar
• Ingold I, Berndt C, Schmitt S, Doll S, Poschmann G, Buday K, Roveri A, Peng X, Porto Freitas F, Seibt T, et al. Selenium utilization by GPX4 is required to prevent hydroperoxide-induced ferroptosis. Cell. 2018;172(3):409–422 e421. doi:10.1016/j.cell.2017.11.048.
   PubMed Web of Science ®Google Scholar
• Li Y, Huang X, Yang G, Xu K, Yin Y, Brecchia G, Yin J. CD36 favours fat sensing and transport to govern lipid metabolism. Prog Lipid Res. 2022;88:101193. doi:10.1016/j.plipres.2022.101193.
   PubMed Web of Science ®Google Scholar
• Ma X, Xiao L, Liu L, Ye L, Su P, Bi E, Wang Q, Yang M, Qian J, Yi Q, et al. CD36-mediated ferroptosis dampens intratumoral CD8+ T cell effector function and impairs their antitumor ability. Cell Metab. 2021;33(5):1001–1012.e5. doi:10.1016/j.cmet.2021.02.015.
   PubMed Web of Science ®Google Scholar
• Xu S, Chaudhary O, Rodriguez-Morales P, Sun X, Chen D, Zappasodi R, Xu Z, Pinto AFM, Williams A, Schulze I, et al. Uptake of oxidized lipids by the scavenger receptor CD36 promotes lipid peroxidation and dysfunction in CD8+ T cells in tumors. Immunity. 2021;54(7):1561–1577.e7. doi:10.1016/j.immuni.2021.05.003.
   PubMed Web of Science ®Google Scholar
• Shen DD, Pang JR, Bi YP, Zhao L-F, Li Y-R, Zhao L-J, Gao Y, Wang B, Wang N, Wei L, et al. LSD1 deletion decreases exosomal PD-L1 and restores T-cell response in gastric cancer. Mol Cancer. 2022;21(1):75. doi:10.1186/s12943-022-01557-1.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Shi J, Liu X, Feng L, Gong Z, Koppula P, Sirohi K, Li X, Wei Y, Lee H, et al. BAP1 links metabolic regulation of ferroptosis to tumour suppression. Nat Cell Biol. 2018;20(10):1181–1192. doi:10.1038/s41556-018-0178-0.
   PubMed Web of Science ®Google Scholar
• Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov. 2015;14(9):642–662. doi:10.1038/nrd4663.
   PubMed Web of Science ®Google Scholar
• Shalhout SZ, Miller DM, Emerick KS, Kaufman HL. Therapy with oncolytic viruses: progress and challenges. Nat Rev Clin Oncol. 2023;20(3):160–177. doi:10.1038/s41571-022-00719-w.
   PubMed Web of Science ®Google Scholar
• Yu M, Benjamin MM, Srinivasan S. Morin, E.E., Shishatskaya, E.I, Schwendeman, S.P. and Schwendeman, A. Battle of GLP-1 delivery technologies. Adv Drug Deliv Rev. 2018;130:113–130. doi:10.1016/j.addr.2018.07.009.
   PubMed Web of Science ®Google Scholar
• Zalevsky J, Chamberlain AK, Horton HM, Karki S, Leung IWL, Sproule TJ, Lazar GA, Roopenian DC, Desjarlais JR. Enhanced antibody half-life improves in vivo activity. Nat Biotechnol. 2010;28(2):157–159. doi:10.1038/nbt.1601.
   PubMed Web of Science ®Google Scholar
• Deting Gong MC, Wang Y, Wang Y, Shi J, Hou Y. Juanjuan Shi and Yongzhong Hou: role of ferroptosis on tumor progression and immunotherapy. Cell Death Discovery. 2022;8(1):427. doi:10.1038/s41420-022-01218-8.
   PubMed Web of Science ®Google Scholar
• Matsushita M, Freigang S, Schneider C, Conrad M, Bornkamm GW, Kopf M. T cell lipid peroxidation induces ferroptosis and prevents immunity to infection. J Exp Med. 2015;212(4):555–568. doi:10.1084/jem.20140857.
   PubMed Web of Science ®Google Scholar
• Xu C, Sun S, Johnson T, Qi R, Zhang S, Zhang J, Yang K. The glutathione peroxidase Gpx4 prevents lipid peroxidation and ferroptosis to sustain Treg cell activation and suppression of antitumor immunity. Cell Rep. 2021;35(11):109235. doi:10.1016/j.celrep.2021.109235.
   PubMed Web of Science ®Google Scholar
• Yao Y, Chen Z, Zhang H, Chen C, Zeng M, Yunis J, Wei Y, Wan Y, Wang N, Zhou M, et al. Selenium–GPX4 axis protects follicular helper T cells from ferroptosis. Nat Immunol. 2021;22(9):1127–1139. doi:10.1038/s41590-021-00996-0.
   PubMed Web of Science ®Google Scholar
• Chesney JA, Puzanov I, Ross MI, Collichio FA, Milhem MM, Chen L, Kim JJ, Garbe C, Hauschild A, Andtbacka RHI, et al. Primary results from a randomized (1:1), open-label phase II study of talimogene laherparepvec (T) and ipilimumab (I) vs I alone in unresected stage IIIB- IV melanoma. J Clin Oncol. 2017;35(15_suppl):9509–9509. doi:10.1200/JCO.2017.35.15_suppl.9509.
   Google Scholar
• Antoni Ribas RD, Puzanov I, VanderWalde A, Andtbacka RHI, Michielin O, Olszanski AJ, Malvehy J, Cebon J, Fernandez E, Kirkwood JM, et al. Long: oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. Cell. 2017;170(6):1109–1119.e1110. doi:10.1016/j.cell.2017.08.027.
   PubMed Web of Science ®Google Scholar